Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cabaletta Bio

1.99
+0.190010.56%
Post-market: 1.98-0.0107-0.54%19:50 EDT
Volume:4.57M
Turnover:8.63M
Market Cap:178.99M
PE:-0.78
High:2.00
Open:1.75
Low:1.70
Close:1.80
Loading ...

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Jun

Promising Clinical Data from Cabaletta Bio’s RESET Trial Supports Buy Rating

TIPRANKS
·
12 Jun

Promising Efficacy and Strategic Advancements: Douglas Tsao’s Buy Rating on Cabaletta Bio

TIPRANKS
·
12 Jun

Cabaletta Bio Announces Pricing of Public Offering of Securities

THOMSON REUTERS
·
11 Jun

Cabaletta Bio Inc - Combined Offering Price Set at $2.00 per Share and Warrant

THOMSON REUTERS
·
11 Jun

Cabaletta Bio Inc. Announces Public Offering of Common Stock and Warrants to Raise Capital

Reuters
·
11 Jun

Cabaletta Bio Announces Proposed Public Offering of Securities

THOMSON REUTERS
·
11 Jun

Cabaletta Bio Inc - Co and TD Cowen Terminate Sales Agreement - SEC Filing

THOMSON REUTERS
·
11 Jun

Cabaletta Bio Unveils Promising Clinical Data for Rese-cel in Myositis, Lupus, and Scleroderma at EULAR 2025 Congress

Reuters
·
11 Jun

Cabaletta Bio Announces New Rese-Cel Safety and Efficacy Data in Patients With Myositis, Lupus and Scleroderma to Be Presented at the Eular 2025 Congress

THOMSON REUTERS
·
11 Jun

Cabaletta Bio Stockholders Approve Key Proposals

TIPRANKS
·
10 Jun

Cabaletta Bio Inc - Stockholders Approve Increase in Authorized Shares From 150 Mln to 300 Mln - SEC Filing

THOMSON REUTERS
·
10 Jun

Cabaletta Bio Inc. Held Annual Stockholders Meeting

Reuters
·
10 Jun

Cabaletta Bio Reprices Stock Options to Motivate Staff

TIPRANKS
·
20 May

Cabaletta Bio Inc. Announces Repricing of Stock Options to Retain and Motivate Employees

Reuters
·
20 May

Cabaletta Bio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
17 May

UBS Adjusts Price Target on Cabaletta Bio to $6 From $7, Maintains Buy Rating

MT Newswires Live
·
16 May

Cabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating

TIPRANKS
·
16 May

Cabaletta Bio Extends Gains Premarket as FDA Meeting Fuels Expectations for Myositis BLA Submission

MT Newswires Live
·
16 May

Cabaletta Bio price target lowered to $13 from $17 at Citi

TIPRANKS
·
16 May